SABS Latest News, Press Relases and Analysis

All

Press Releases

13 days ago - By: SAB Biotherapeutics, Inc.

SAB BIO Reports Third Quarter Financial Results and Recent Business Highlights

13 days ago - By: SAB Biotherapeutics, Inc.

SAB BIO Reports Third Quarter Financial Results and Recent Business Highlights

22 days ago - By: SAB Biotherapeutics, Inc.

SAB BIO to Present Data at the International Society for Pediatric and Adolescent Diabetes Annual Conference Showcasing Progress in the Development of SAB-142

22 days ago - By: SAB Biotherapeutics, Inc.

SAB BIO to Present Data at the International Society for Pediatric and Adolescent Diabetes Annual Conference Showcasing Progress in the Development of SAB-142

10 months ago - By: Benzinga

Why Is SAB BIO Stock Trading Lower On Tuesday?

22 days ago - By: SAB Biotherapeutics, Inc.

SAB BIO to Participate in Upcoming Investor Conferences

2 months ago - By: Benzinga - Mentions: PRPH ABP WORX COSM ...

12 Health Care Stocks Moving In Friday's After-Market Session

2 months ago - By: SAB Biotherapeutics, Inc.

SAB BIO Highlights Data in Multiple Presentations at EASD

2 months ago - By: SAB Biotherapeutics, Inc.

SAB BIO Highlights Data in Multiple Presentations at EASD

3 months ago - By: SAB Biotherapeutics, Inc.

SAB BIO to Deliver Five Presentations Related to SAB-142 at the 2025 Annual Meeting of the European Association for the Study of Diabetes

3 months ago - By: SAB Biotherapeutics, Inc.

SAB BIO to Deliver Five Presentations Related to SAB-142 at the 2025 Annual Meeting of the European Association for the Study of Diabetes

4 months ago - By: Zacks Investment Research - Mentions: ABSI

SAB Biotherapeutics, Inc. (SABS) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

4 months ago - By: SAB Biotherapeutics, Inc.

SAB BIO Reports Second Quarter Financial Results and Highlights Company Updates

4 months ago - By: SAB Biotherapeutics, Inc.

SAB BIO Reports Second Quarter Financial Results and Highlights Company Updates

4 months ago - By: SAB Biotherapeutics, Inc.

SAB BIO Announces Oversubscribed $175 Million Private Placement

4 months ago - By: SAB Biotherapeutics, Inc.

SAB BIO Announces Oversubscribed $175 Million Private Placement

7 months ago - By: SAB Biotherapeutics, Inc.

SAB BIO Announces Q1 2025 Financial Results and Provides Company Updates

7 months ago - By: SAB Biotherapeutics, Inc.

SAB BIO Announces Q1 2025 Financial Results and Provides Company Updates

7 months ago - By: Zacks Investment Research - Mentions: OCS

Oculis Holding AG (OCS) Reports Q1 Loss, Tops Revenue Estimates

7 months ago - By: Zacks Investment Research - Mentions: ARQT

Arcutis Biotherapeutics, Inc. (ARQT) Reports Q1 Loss, Tops Revenue Estimates

8 months ago - By: SAB Biotherapeutics, Inc.

SAB BIO Reports Full Year 2024 Operating and Financial Results

8 months ago - By: SAB Biotherapeutics, Inc.

SAB BIO Reports Full Year 2024 Operating and Financial Results

10 months ago - By: SAB Biotherapeutics, Inc.

SAB BIO to Participate in Upcoming Investor Conferences

10 months ago - By: SAB Biotherapeutics, Inc.

SAB BIO to Participate in Upcoming Investor Conferences

10 months ago - By: SAB Biotherapeutics, Inc.

SAB BIOTHERAPEUTICS INC (SABS) Stock News

SABS Latest News, Press Relases and Analysis

SAB BIO Reports Third Quarter Financial Results and Recent Business Highlights

SAB BIO Reports Third Quarter Financial Results and Recent Business Highlights

SAB BIO to Present Data at the International Society for Pediatric and Adolescent Diabetes Annual Conference Showcasing Progress in the Development of SAB-142

SAB BIO to Present Data at the International Society for Pediatric and Adolescent Diabetes Annual Conference Showcasing Progress in the Development of SAB-142

Why Is SAB BIO Stock Trading Lower On Tuesday?

SAB BIO to Participate in Upcoming Investor Conferences

12 Health Care Stocks Moving In Friday's After-Market Session

SAB BIO Highlights Data in Multiple Presentations at EASD

SAB BIO Highlights Data in Multiple Presentations at EASD

SAB BIO to Deliver Five Presentations Related to SAB-142 at the 2025 Annual Meeting of the European Association for the Study of Diabetes

SAB BIO to Deliver Five Presentations Related to SAB-142 at the 2025 Annual Meeting of the European Association for the Study of Diabetes

SAB Biotherapeutics, Inc. (SABS) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

SAB BIO Reports Second Quarter Financial Results and Highlights Company Updates

SAB BIO Reports Second Quarter Financial Results and Highlights Company Updates

SAB BIO Announces Oversubscribed $175 Million Private Placement

SAB BIO Announces Oversubscribed $175 Million Private Placement

SAB BIO Announces Q1 2025 Financial Results and Provides Company Updates

SAB BIO Announces Q1 2025 Financial Results and Provides Company Updates

Oculis Holding AG (OCS) Reports Q1 Loss, Tops Revenue Estimates

Arcutis Biotherapeutics, Inc. (ARQT) Reports Q1 Loss, Tops Revenue Estimates

SAB BIO Reports Full Year 2024 Operating and Financial Results

SAB BIO Reports Full Year 2024 Operating and Financial Results

SAB BIO to Participate in Upcoming Investor Conferences

SAB BIO to Participate in Upcoming Investor Conferences

SAB BIO Announces Positive Topline Phase 1 Clinical Results with Potentially Disease-Modifying T1D Therapy SAB-142